Some studies associated CYP2C19 variants with major depressive disorder development, a longer history of depression, prolonged depressive episodes, and greater symptom severity. Other studies reported no such association, and the review notes that inconsistencies remain across populations and studies.

This systematic review and meta-analysis evaluated randomised controlled trials of pharmacogenomic tests involving CYP2D6 and CYP2C19 polymorphisms in major depression. It found that pharmacogenomic tests were more effective than treatment as usual for improvement, response, and remission, supporting clinical relevance of these variants in depression treatment outcomes.

The review states that CYP2C19 genomic variants provide the most reliable actionable approach to guide choice and dosing of antidepressants in major depression. It also reports that twelve randomized controlled trials were included and that pharmacogenomic tests improved improvement, response, and remission outcomes.

The study reports that CYP2C19 phenotype variants may be associated with increased adverse drug reactions to psychotropic drugs. It specifically says that, for CYP2C19, elevated adverse drug reaction risk was observed for both poor metabolizers and rapid metabolizers.

The authors state that the study "is the first to examine the association between the CYP2C19 genotype and the steady-state plasma concentration of escitalopram" in patients with major depressive disorder (MDD) treated under naturalistic conditions. They investigated the relationship between CYP2C19 *loss‑of‑function and increased function alleles* and escitalopram/desmethylescitalopram concentrations, concluding that CYP2C19 genotypes significantly affect plasma levels, which may in turn influence clinical response and tolerability in MDD patients.

MedlinePlus explains that the CYP2C19 gene encodes a liver enzyme that metabolizes several drugs, including some antidepressants such as citalopram and escitalopram. It describes how genetic changes in CYP2C19 lead to poor, intermediate, extensive, or ultrarapid metabolizer phenotypes, which can change blood levels and effectiveness of these medications. The page lists drug‑metabolism–related effects and certain disease associations but does not identify CYP2C19 variants as established risk factors for developing major depressive disorder or for longer or more severe depressive episodes.

The abstract states: "Some studies associated variants with MDD development, a more extended history of depression, prolonged depressive episodes, and symptom severity, while others reported no such association." The review explains that it "assessed the variation in common CYP2C19 gene variants' frequencies across populations with MDD, evaluating their impact on clinical characteristics and treatment response." It concludes that "inconsistencies highlight the need for further research to clarify the role of these polymorphisms in MDD and optimize treatment strategies."

The paper notes that the CYP2C19 enzyme metabolizes several antidepressants and that "polymorphisms in the corresponding gene CYP2C19 influence plasma concentration and hence treatment outcomes in major depressive disorder." It reports that in a large study of antidepressant treatment in bipolar depression, slower CYP2C19 metabolism was associated with a higher risk of treatment‑emergent mania, but there were "no clear associations with early treatment persistence, treatment discontinuation, and switching to a new antidepressant." The study focuses on treatment outcomes and emergent mania risk rather than on the incidence of MDD, episode duration, or baseline symptom severity.

According to the abstract, this study evaluated "the effect of CYP2C19 genetic polymorphism on the efficacy and safety profiles of citalopram" in 130 patients with major depressive disorder. CYP2C19 poor metabolizers had significantly higher steady‑state serum concentrations of citalopram than normal metabolizers, and the authors reported differences in adverse effects related to these concentrations. The article examines pharmacokinetics and medication response in MDD but does not state that CYP2C19 variants are associated with developing MDD, longer episode duration, or greater baseline depressive symptom severity.

This study reports that a CYP2C19-linked expression quantitative trait locus (eQTL) influences both gene expression and depression-related phenotypes. The authors state that elevated CYP2C19 expression was "associated with an increase in depressive symptoms" and that these genetic effects were accompanied by "hippocampal homeostasis impairment" in human and experimental data. They conclude that CYP2C19 variation affecting expression "may contribute to individual differences in susceptibility to depressive symptoms."

The authors hypothesized that "CYP2C19 polymorphisms are associated with major depressive disorder (MDD) remission in patients treated with escitalopram in the long term" and evaluated clinical outcomes in relation to CYP2C19 genotype. They examined remission and response to escitalopram rather than the risk of developing MDD itself or the natural duration and severity of depressive episodes in the absence of treatment. The focus is on how CYP2C19 variation affects antidepressant treatment outcomes, not on an inherent association between CYP2C19 genotype and depressive episode length or symptom severity.

This meta-analysis of GWAS-based pharmacogenetic data examined CYP2C19 metabolizer status in relation to SSRI outcomes. The abstract notes that CYP2C19 polymorphisms "predict citalopram/escitalopram efficacy and side effects," indicating that genetically determined CYP2C19 activity is associated with variation in antidepressant treatment response. While the main focus is on drug response, the findings support a role of CYP2C19 genetic variation in clinical manifestations of depression under treatment, such as symptom improvement and residual severity.

The abstract explains that previous GWAS of depression had "mostly negative findings" and that this study instead investigated "a broad phenotype from depressive symptoms to major depressive disorder." It reports that the analysis of "9,240 European ancestry cases, 9,519 European ancestry controls, 51,150 European ancestry individuals with depressive symptom measurement" identified a genome-wide significant locus for this broad depression phenotype. This work illustrates how GWAS approaches have been used to identify genetic loci associated with both depressive symptoms and MDD, providing context for evaluating whether CYP2C19 appears among risk loci.

This large trans-ancestry GWAS reports that it "identified 697 variants and 308 genes associated with depression" across diverse populations. The authors note that the implicated biology "involves postsynaptic density, neuronal dysregulation, and amygdala" function. The extensive list of genome-wide significant loci provides a reference set of depression-associated genes and variants; inspection of these results in the paper and its supplements can be used to check whether CYP2C19 is included among genes robustly associated with depression diagnosis in population-based GWAS.

In this retrospective study of patients with major depressive disorder (MDD), the authors examine outcomes after implementing pharmacogenetic testing. The abstract states: "Our findings suggest that the implementation of pharmacogenetic testing based on CYP2C19 could be clinically useful in guiding antidepressant treatment." The focus is on treatment response and adverse effects rather than the risk of developing MDD, but it supports a link between CYP2C19 genotype and clinical course and treatment outcomes of depression.

The portal summarizes the landmark Psychiatric Genomics Consortium MDD GWAS by Wray et al. It notes that the study "analyzed genetic associations with major depressive disorder (MDD) in 135,458 cases and 344,901 control subjects" and that the genome-wide analyses "identify 44 risk variants" which refine the genetic architecture of MDD. These 44 loci, derived from a large European-ancestry sample, serve as another reference set of confirmed MDD risk variants against which to check whether CYP2C19 has been implicated as a major depression risk gene in unbiased GWAS.

This review states that "CYP2C19 polymorphism can influence the metabolism of SSRIs (citalopram, escitalopram, and sertraline) due to its variability in enzyme activities, which includes both loss‑of‑function (*2, *3) and gain‑of‑function (*17) polymorphisms." It explains that these genetic variations lead to "significant changes in drug efficacy and safety" among individual patients with major depressive disorder and highlights the importance of considering CYP2C19 genotype when prescribing SSRIs. The article discusses metabolism, efficacy, and safety, but it does not claim that CYP2C19 variants are associated with longer depressive episodes or greater depressive symptom severity independent of medication effects.

In this clinical pharmacogenetic study of patients with major depressive disorder treated with SSRIs, the authors investigated whether CYP2C19 metabolizer status predicted treatment response and side‑effects. They reported that poor metabolizers had higher drug levels and an altered side‑effect profile, and they examined remission and response rates. The paper addresses antidepressant response but does not report that CYP2C19 genetic variants are associated with the presence of MDD, the intrinsic duration of depressive episodes, or greater depressive symptom severity outside of treatment response.

This review discusses pharmacogenetics in MDD and states that genetic variability in cytochrome enzymes, including "functional genetic variants in genes coding for cytochrome enzymes (CYP2D6 and CYP2C19)," leads to differing metabolizer statuses that influence antidepressant plasma levels and clinical response. It describes how these variants can contribute to variability in treatment outcomes, including symptom improvement and side effects, though it does not specifically quantify associations with length or severity of depressive episodes.

This review summarizes evidence that CYP2C19 polymorphisms influence the pharmacokinetics of several SSRIs and can affect treatment response and adverse reactions in major depressive disorder. It notes that CYP2C19 poor metabolizers often have higher serum SSRI concentrations and may experience more side‑effects, whereas ultrarapid metabolizers may have lower concentrations and reduced efficacy. The review emphasizes pharmacokinetic and treatment‑outcome associations but does not report that CYP2C19 genetic variants are directly associated with major depressive disorder diagnosis, longer depressive episode duration, or inherently greater depressive symptom severity.

The meta-analysis reported that CYP2C19 poor metabolizers had a higher risk of side effects during the first month of treatment, but also higher remission rates and better symptom improvement after 2 to 3 months. The article also notes that CPIC, DPWG, and drug regulators consider CYP2C19 and CYP2D6 the variants with sufficient support.

This study examined the effect of the CYP2C19*17 increased‑function allele on escitalopram treatment outcomes in patients with major depressive disorder. The authors evaluated response and remission rates and reported that CYP2C19*17 carriers showed altered escitalopram pharmacokinetics and differences in clinical response. The article analyses treatment response parameters but does not state that CYP2C19*17 or other CYP2C19 variants are associated with having MDD, longer depressive episode duration, or higher baseline depressive symptom severity.

This research news article describes the multi-ancestry GWAS for major depression led by University College London. It explains that the study "linked 53 genome locations to major depression risk not previously identified in studies based on people with European ancestors" and that in total the team found "more than 50 new genetic loci and 205 novel genes that are associated with depression." The article clarifies that these findings come from a GWAS of major depression across European and non-European ancestries, contextualizing which genes have strong statistical evidence of association with depression risk.

In this case–control study of Han Chinese individuals, the authors investigated CYP2C19 polymorphisms and MDD risk. They report that the minor allele frequency of CYP2C19*3 "was significantly higher in MDD patients than in controls" and that carriers of the *3 allele had an increased odds ratio for MDD compared with non-carriers. The paper concludes that CYP2C19 loss-of-function variants "might confer susceptibility to major depressive disorder" in this population, providing direct evidence of an association between specific CYP2C19 genetic variants and MDD diagnosis.

The article summarizes clinical evidence on CYP2C19 and antidepressant outcomes in MDD. It notes: "Candidate genes involved in the metabolism of antidepressants, mainly CYP2D6 and CYP2C19, are documented in clinical guidelines and currently used in clinical settings." It also states that a recent study "demonstrated that CYP2C19-poor metabolizers have an increased risk of gastrointestinal, neurological, and sexual side effects, but also benefit from higher symptom improvement and better chances of symptom remission." The piece describes evidence as still weak and focused on treatment effects rather than the initial development or duration of depression.

In a broad review of pharmacogenetics in depression, the authors describe CYP2C19 as one of the key enzymes metabolizing citalopram, escitalopram, and sertraline, and they summarize evidence that CYP2C19 polymorphisms affect antidepressant plasma concentrations and side‑effect risk. They discuss that poor and ultrarapid metabolizers can experience altered efficacy or tolerability. However, the review does not present data that CYP2C19 genetic variants are associated with major depressive disorder susceptibility or with longer or more severe depressive episodes independent of antidepressant treatment.

This Japanese study examined whether CYP2C19 polymorphisms were associated with depression and anxiety disorders. The authors state that they found "a significant association between CYP2C19 poor metabolizer genotype and susceptibility to depression" in their sample. They further report that individuals with CYP2C19 genotypes conferring reduced enzyme activity had a higher prevalence of depressive disorders compared with extensive metabolizers, indicating an association between CYP2C19 genetic variation and risk of depressive illness.

This meta-analysis describes itself as the first to investigate how CYP2C19 polymorphisms predict citalopram and escitalopram efficacy and side effects. The abstract frames CYP2C19 metabolizing activity as relevant to antidepressant response and adverse effects, which is supportive context for depression-treatment associations.

Reporting on a cost-effectiveness analysis, the article explains that researchers "studied 125 patients with MDD" and evaluated pharmacogenetic testing including CYP2C19. It notes that "CYP2C19 genotyping … would be cost effective at a national level" for guiding antidepressant choice. The focus is economic and on treatment response, not on whether CYP2C19 variants are associated with the risk, duration, or severity of major depressive disorder.

In this clinical genetics study, researchers assessed CYP2C19 genotype in patients with depression and evaluated associations with both disease and treatment outcomes. They report that certain CYP2C19 genotypes were "more frequent in patients with major depressive disorder compared with controls" and that metabolizer status was related to the course of illness and antidepressant response. The findings suggest that CYP2C19 genetic variants may be linked not only to antidepressant pharmacokinetics but also to aspects of depressive disorder susceptibility and symptom trajectory.

This randomized, double-blind clinical trial in MDD assesses "the clinical impact of integrated pharmacogenomic testing" including CYP2C19-guided treatment. The registry description explains that the study aims to evaluate whether incorporating pharmacogenomic information improves treatment outcomes in major depressive disorder. It reflects ongoing interest in how CYP2C19 and other variants relate to treatment course, but does not itself provide published results on associations with MDD duration or symptom severity.

The indexed summary states that variation in common CYP2C19 gene variant frequencies across MDD populations varied between studies, and that treatment tolerability and symptom improvement also varied. This is secondary indexing rather than primary evidence, but it reflects the study's reported focus on CYP2C19 and depressive outcomes.

Clinical pharmacogenetics guidance has long treated CYP2C19 as relevant to antidepressant exposure and treatment response for several SSRIs, especially citalopram, escitalopram, and sertraline. This supports the broader plausibility of CYP2C19-related differences in depressive treatment outcomes, though it does not by itself establish a causal association with major depressive disorder incidence or episode duration.